Every day, emergency rooms receive people who have taken a blow to the head, and too often the first scan comes back clean and the person goes home still unwell. In a quiet but consequential study from the University of Pittsburgh, researchers have looked for a way to read the body's own signals of injury. Their finding suggests that a simple blood measurement of a protein released by injured brain cells may help separate those who truly have hidden damage from those who do not. It is a modest step, but it speaks to an old human difficulty: the injury we cannot see is often the one that linger
Blood Test Could Help Clinicians Spot Brain Injuries That CT Scans Miss in Mild TBI Patients
Roughly 2.8 million Americans experience a TBI each year, with significant mortality, morbidity and long-term disability; many patients with negative CT scans remain symptomatic.
We're sending people home with a negative CT scan, but one in four have an abnormality on MRI
Mark
So what's actually new here? Blood tests for brain injury already exist.
Mimi
The existing test helps decide whether a CT is needed. This study flips it: it sets cutoffs for how high GFAP must be to be fairly sure there is an injury, including ones CT misses.
Mark
And that matters because CT is the gatekeeper?
Mimi
Yes. About 25% of patients with a negative CT have an MRI abnormality, yet they get sent home. Over 50% of mild TBI participants in TRACK-TBI had functional limits at one year.
Luke
Careful with that link. Eagle suspects missed identification drives those poor outcomes. That's a hypothesis, not something the study shows.
Mark
Fair. Why did GFAP work better than UCH-L1?
Mimi
GFAP, from glial cells, spikes between four and 20 hours and declines slowly, so it stays detectable. UCH-L1, from neurons, was less able to separate the groups here.
Luke
The source doesn't say why, and it doesn't give the actual cutoff values or accuracy figures. So we can't say how often the test would be wrong.
Mark
And the bedside version?
Mimi
A whole-blood point-of-care test now exists, so no lab send-out. Eagle's team is working to put it into routine ED use.
Luke
Working toward it isn't the same as doing it. And predicting long-term outcomes is only something he's exploring.
Der Puls
- A negative head CT can send a patient home even when roughly one in four still carries brain damage that only MRI reveals.
- Mild brain injuries are easy to miss, and many patients remain symptomatic for months with no clear explanation.
- Researchers are testing blood levels of GFAP and UCH-L1 to find cutoffs that separate real injury from none.
- A bedside, whole-blood version of the test now allows results without waiting on a lab, moving the idea closer to the emergency room floor.
- The team is working to bring the test into daily ED practice and is asking whether these markers can forecast long-term recovery.
Every day, emergency rooms receive people who have taken a blow to the head, and too often the first scan comes back clean and the person goes home still unwell. In a quiet but consequential study from the University of Pittsburgh, researchers have looked for a way to read the body's own signals of injury. Their finding suggests that a simple blood measurement of a protein released by injured brain cells may help separate those who truly have hidden damage from those who do not. It is a modest step, but it speaks to an old human difficulty: the injury we cannot see is often the one that lingers longest.
A patient arrives at an emergency department after a blow to the head. The CT scan is run, as it usually is, and it comes back negative. The patient goes home. New research from the University of Pittsburgh suggests that about one in four people in this position has an abnormality that an MRI would reveal, the kind of finding that should lead to specialized follow-up.
The study, published in the Journal of Neurosurgery, was led by neurosurgery clinician-scientists at Pitt. The team reports cutoff levels for two brain-associated proteins that can be measured in the blood after injury. They argue these may help clinicians identify traumatic brain injury that would otherwise go unrecognized. The stakes are large: roughly 2.8 million Americans sustain a TBI each year, and many who seem to recover fully still struggle. In an earlier multicenter study, more than half of people with mild brain injuries had functional limits a year later.
The lead author, Shawn Eagle, suspects that a major reason for these poor outcomes is simple: patients are not being properly identified. Without a positive CT, there has been no objective way to know whether a brain injury exists. CT remains the first-line tool because it is cheap, fast and widely available, but it misses intracranial damage that MRI can detect. MRI, however, is slow and costly, and not suited to triage.
The proteins at the center of the work, GFAP and UCH-L1, rise in the blood soon after injury and then fall. Within 24 hours, GFAP levels could distinguish patients with acute brain injury from those with no evidence of pathology. UCH-L1 was less effective in this study. A point-of-care, whole-blood version of the test can now be run at the bedside, without sending samples to a lab.
Eagle's team is working to bring the test into everyday emergency care, and is exploring whether blood biomarkers might also predict who will face long-term difficulties. For patients who leave the ED with a clean scan and lingering symptoms, that possibility offers a route toward being believed and properly cared for.
A patient comes into an emergency department after a blow to the head. A CT scan is run, as it usually is, and it comes back negative. The patient goes home. According to new research from the University of Pittsburgh, about one in four patients in that position has an abnormality that shows up on MRI, the kind of finding that should trigger specialized follow-up care.
The study, published in the Journal of Neurosurgery, comes from a multi-institutional team led by neurosurgery clinician-scientists at the University of Pittsburgh School of Medicine. It reports clinical cutoffs for two brain-associated proteins that can be detected in the blood after injury, and argues they may help clinicians identify and triage patients with traumatic brain injury, or TBI, whose diagnosis might otherwise be missed.
The scale of the problem is large. Roughly 2.8 million people in the U.S. experience a TBI each year, with significant mortality, morbidity and long-term disability. Shawn Eagle, Ph.D., an assistant professor in Pitt's Department of Neurological Surgery and the study's lead author, described long-term outcomes for people seen in the emergency department as amazingly poor. Earlier findings from TRACK-TBI, a multicenter, longitudinal study, showed that more than 50% of participants with a mild brain injury had functional limitations a year later.
Pitt's Neurotrauma Clinical Trials Center collects data and biospecimens from TBI patients arriving at the ED for that study, and serves as its primary biorepository. The center is led by David Okonkwo, M.D., Ph.D., professor of neurological surgery at Pitt and director of neurotrauma at UPMC, and Ava Puccio, R.N., Ph.D., associate professor of neurological surgery at Pitt. Eagle suspects a major driver of the poor outcomes is that patients are not being properly identified. Before this research, he said, without a positive CT scan there was no objective way to know whether you had a brain injury.
CT is the first-line tool for good reasons: it is inexpensive, widely available and quick. But about 25% of patients have intracranial pathology that it misses. MRI gives a more sensitive, detailed look at brain tissue, yet it is slow, costly and unsuited to triage in an emergency setting. Many patients with normal CT scans keep having symptoms.
The proteins at the center of the work are glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase-L1 (UCH-L1). Both rise in the bloodstream right after injury and fall over time. A test measuring them can already help clinicians decide whether a CT is needed in mild TBI, ruling out unnecessary imaging in 15 minutes. Eagle's team asked the question from the other direction: at what level could a clinician be fairly certain that someone does have a bleed, versus certain that they do not? They also tested whether the proteins could separate patients with a negative CT but positive MRI from those with negative results on both.
Within 24 hours of injury, they found, GFAP levels could distinguish patients with acute brain injury from those with no evidence of pathology on neuroimaging. GFAP is released from glial cells and spikes sharply between four and 20 hours after injury, then declines slowly over the following days. UCH-L1, released from neurons, was less able to tell the groups apart in this study.
A point-of-care, whole-blood version of the test is now available, which makes the approach more practical: it can be run at the bedside instead of requiring samples to be sent to a lab. Eagle said his team is working to bring it into daily ED practice. He expects wider adoption to open up broader uses, and he is exploring whether blood biomarkers could help predict long-term outcomes after TBI.
Bemerkenswerte Zitate
Prior to this research, in the absence of a positive CT scan, there was no objective way to identify if you had a brain injury.— Shawn Eagle, Ph.D., University of Pittsburgh
We're working to incorporate this test into the daily clinical practice in the ED.— Shawn Eagle, Ph.D., University of Pittsburgh
Möchten Sie die ganze Geschichte?
Das Original lesen bei Medical Xpress ↗
Education